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Resistant and disseminated Strongyloides stercoralis infection in a young patient with adult 
T-cell leukemia/lymphoma
Adult T-cell leukemia/lymphoma (ATLL) is a mature T-cell malignancy associated to 
the human T-cell lymphotropic virus type 1 (HTLV-1). There are between 10 and 20 million 
HTLV-1 carriers worldwide, particularly in Southwest Japan, the Caribbean, Central Africa, 
South America and Papua New-Guinea.
In developed countries the median age of patients with ATLL is 60 years, however this 
is lower in developing countries. In Brazil rare cases have been described in infancy. This 
earlier incidence of ATLL may be linked to an excess of antigenic stimuli caused by chronic 
and multiple parasitic infections commonly seen in poor countries(1).
This article reports on an ATLL case in a young woman with massive and refractory 
Strongyloides stercoralis infection. 
 A 17-year-old woman came to the Hospital das Clínicas da Faculdade de Medicina da 
Universidade de São Paulo with abdominal pain and diarrhea that caused a 13 kg weight loss. 
Strongyloidiasis, giardiasis and esophageal candidiasis were identified. Despite of several different 
therapies including specific treatment, the intestinal strongyloidiasis had persisted for one year 
when the patient returned to the hospital with sepsis and aseptic meningitis and a HTLV1 infection 
was detected. A computerized tomography showed enlargement of mesenteric and lung hilum 
lymph nodes and a lymph node biopsy revealed reactive lymphoid hyperplasia. Three months later 
wart-like lesions were noticed on the hands and right knee and blood counts showed hemoglobin 
was 14 g/L, platelet count 156 x 109/L, the white blood cell count was 5 x 109/L, lymphocytes were 
1.5 x 109/L and flower cells were identified in the blood smear. The immunophenotype by flow 
cytometry showed abnormal CD3dim, CD4bright, CD25dim and CD7- T-cell lymphocytes (Figure 1). 
A monoclonal pattern of HTLV-1 insertion into the neoplastic cells was identified by inverse long 
polymerase chain reaction (ILPCR) (Figure 2). A smoldering ATLL was diagnosed and treatment 
with 3 million units of interferon alpha twice per week and zidovudine 900 mg/day was started. The 
patient remained with itching and intermittent diarrhea, despite of the treatment for strongyloidiasis. 
After one year the disease progressed with neck, axillary and inguinal lymphadenopathy and 
splenomegaly. Finally, the patient was admitted to the emergency department in a bad health state 
with cough, fever, tracheobronchitis and hypercalcemia. Regardless of treatment the patient died 
after four days due to disseminated Strongyloides stercoralis infection. 
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Figure 1 - Flow cytometry analysis
Cytograms of flow cytometry in dot plot showing the phenotype of the T-cell population of adult T-cell 
leukemia/lymphoma. The neoplastic cells were CD3dim, CD4bright, CD7(-), CD25dim and CD19(-)
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Discussion
HTLV-1 belongs to the delta retrovirus group and its pro-viral 
genome shows gag, pol and env genes and a long terminal repeat 
region (LTR) at both ends. A codifying region of the viral genome 
named pX is found between the env gene and 3’-LTR; this region 
is responsible for the synthesis of the viral regulatory proteins 
p40 (Tax), p27 (Rex), p12, p13, p21, p30 and b-ZIP factor 
(HBZ) which are implicated in viral infectivity and proliferation 
of infected cells. This virus is disseminated by breast feeding, 
syringe sharing, blood transfusions and sexual intercourse. There 
is a long latency until ATLL develops and only 3% to 5% of 
HTLV-1 carriers will become sick(2).
After cells are infected by HTLV-1, they form virological 
synapses with target cells of the host resulting in transference of 
viral RNA to the target cell. A pro-viral DNA is produced from the 
viral RNA mediated by the viral reverse transcriptase enzyme. The 
viral DNA is randomly inserted into the host’s DNA. But in ATLL 
the malignant cells present a monoclonal pattern of HTLV-1(2). 
Tax and HBZ are essential in the pathogenesis of ATLL 
as they induce viral gene expression by the amplification of 
the LTR and the activation of NF-KB, SRF, CREB and AP-1 
transcription signal genes thus preventing expression of the 
p53 and p16INK4A anti-oncogenes. These tumor suppressor 
genes induce T-cell toxicity and reduce the survival of HTLV-1 
infected cells. Subsequently Tax is suppressed by epigenetic 
factors and leukemic cells may escape from immune surveillance 
and are thus able to proliferate indefinitely. HBZ activates the 
transcription factor E2F(3) and polymorphisms in the HLA A16, 
B4002, B4006 and B4801 genes increase the risk of ATLL 
progression. These polymorphisms are related with a reduced 
T-cell function(3). Diagnosis depends of clinical and laboratorial 
criteria. The laboratorial evaluation includes blood counts, 
smear analysis and lymphocyte immunophenotype. Eosinophilia 
is common and related to a worse prognosis. Lymphocytosis 
with medium-sized flower cells, dense chromatin and nucleus 
with polylobulated or convolute features with a high degree of 
basophilia on cytoplasm is the hallmark of acute and chronic 
ATLL. The common phenotype is CD3dim, CD4bright, CD25dim and 
CD7-, but a double positive CD4+/CD8+ ATLL may occur 
and rare cases may be CD4-/CD8+. 
HTLV-1 must be confirmed by Western-blot with monoclonal 
viral DNA insertion in lymphocytes being the gold standard for 
diagnosis(1,2). Bone marrow aspirate and biopsy is not necessary 
and lymph node biopsy is not enough to make the diagnosis.
The most aggressive and commonest form of the disease is 
acute ATLL (65%) characterized by high lymphocyte counts and 
lactate dehydrogenase (LDH) levels, hepatosplenomegaly, skin 
lesions and hypocalcemia. The lymphoma form has enlargement 
of lymph nodes, visceromegaly, normal or high levels of LDH 
and less than 1% of neoplastic cells in the blood. Smoldering 
and chronic ATLL are more indolent; the first may present skin 
lesions, pulmonary infiltration and a normal lymphocyte count 
with less than 1% to 5% of leukemic cells and normal LDH and 
calcium. Chronic ATLL has less than 4 x 109/L lymphocytes 
and 3% of circulating flower cells(4). 
Skin involvement occurs in 50% of cases with no specific 
findings but macula, plaque, nodule, and purpura or erythrodermic 
eruptions may occur. Macrophage activating syndrome with 
hemophagocytosis may also be found predicting transformation 
to more aggressive forms.
Cellular immunity is compromised in ATLL and 
opportunistic infections with a fatal course such as Pneumocystis 
jiroveci, cytomegalovirus, Strongyloides stercoralis, 
Mycobacterium avium and fungi can arise. About 30% of 
HTLV-1 carriers with strongyloidiasis show a monoclonal 
provirus integration suggesting that this parasite may interfere 
in the pathogenesis of ATLL(5).
ATLL remains incurable and only transitory response can 
be acquired. The most frequent mechanism of chemotherapy 
resistance in ATLL is linked to multiple drug resistance (MDR) 
proteins, mutations of the p53 gene and oncogene abnormalities(4). 
The aggressive subtypes must be treated but a watch and wait 
conduct can be followed for indolent forms. 
If polychemotherapy is indicated, supportive care with 
prophylaxis for viral, fungal and bacterial infections should be 
used as immunodeficiency will be exacerbated by neutropenia 
secondary to treatment.
Intestinal infection by Strongyloides stercoralis is 
common before chemotherapy, even in HTLV-1 carriers. 
Patients with ATLL must be investigated for intestinal 
parasitosis and eradication of parasitosis with ivermectin or 
thiabendazole should be performed before chemotherapy to 
avoid dissemination of the strongyloidiasis. 
The most common regimens for aggressive ATLL are 
anthracycline-based. A study by the Japan Oncology Group 
observed overall survival (OS) of 66% [25% complete 
remission (CR) and 41% partial remission (PR)] with CHOP-14. 
Figure 2 - Polymerase chain reaction diagnostic test
Inverse long polymerase chain reaction in 10% polyacrylamide gel stained with silver 
showing in the 1Kb line: 1 kilobase ladder; Line 1: human T-cell lymphotropic virus 
(HTLV) carrier control 1; Line 2: HTLV carrier control 2; Line 3: HTLV negative 
control; Line 4: adult T-cell leukemia/lymphoma patient; Line 5: HTLV carrier control 3; 
Line 6: HTLV carrier control 4; Line 7: Amplification control
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The 3-year OS was 12.7% with 10.9 months of progression free 
survival (PFS). A sequential aggressive chemotherapy using 
vincristine, cyclophosphamide, doxorubicin and prednisone; 
AMP: doxorubicin, ranimustine and prednisone alternated with 
vindesine, etoposideo, carboplatin and prednisone was better than 
CHOP-14 for acute lymphoma and unfavorable chronic ATLL 
(OS: 72%, CR: 40% and PR: 32%; 3-year OS 23.6% and 
PFS of 12.7 months). This better OS was related to ranimustine 
and carboplatin because they are not linked to MDR resistance.
HTLV-1 carriers might not need to be treated and chronic and 
smoldering ATLL patients do not always need treatment. Smoldering 
and chronic ATLL can be treated with 6 to 9 million units/day of 
interferon alpha plus zidovudine 800-1000 mg/day with a 5-year 
OS of 100%(6). The better response is seen for wild type p53 and low 
interferon regulating factor type 4 (IRF-4) patients. 
In conclusion, although a rare condition, HTLV-1 infection 
and ATLL disease should be included in the differential diagnosis 
of refractory Strongyloides stercoralis infection. In developing 
countries, a young age might not exclude the diagnosis of ATLL. 
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